Skip to main menu Skip to footer
Retina Australia logo
Retina Australia logo
  • About Us
    • What we do
    • Our team
    • Retina Australia celebrates 40 years
    • Membership
    • Supporters and alliances
    • News
    • Reports
    • Contact us
  • Research
    • Research into inherited retinal disease
    • Research impact reports
    • Strategy and governance
    • Apply for grant funding
  • Inherited retinal disease
    • About inherited retinal disease
    • Types of inherited retinal diseases
    • Other retinal dystrophies
    • Genetic testing
    • Clinical trials
    • IRD Research Project and Clinical Trial Register
    • Emerging treatments
    • Frequently asked questions
  • Support
    • Blog
    • Newsletters
    • Webinars and events
    • Guide for the newly diagnosed
    • Other guides for support
    • Community Billboard
    • Eye care professionals
    • Looking after your eyes
    • Vision loss aids
  • Help Us
    • Donate to the 2025 Annual Appeal
    • Do It In The Dark
    • Leave a gift in your will
    • Get Active for Retina Australia
    • Host a fundraiser
    • Become a member
    • Volunteer with us
DONATE
DONATE

Follow us

Visit our Youtube account Visit our Twitter account Visit our Facebook page Visit our Instagram account Visit our Linkedin page

Blog

New Research: The burden of X-linked retinitis pigmentosa (XLRP) on patient experience and patient-reported outcomes

X-linked retinitis pigmentosa (XLRP) is considered one of the...

Read More about New Research: The burden of X-linked retinitis pigmentosa (XLRP) on patient experience and patient-reported outcomes

New Research: The Impacts of Caregiving for Patients with X-Linked RP

X-linked retinitis pigmentosa (XLRP) is considered one of the...

Read More about New Research: The Impacts of Caregiving for Patients with X-Linked RP

New Research: Dismantling barriers to research and clinical care for individuals with a vision impairment

People with vision impairment face limited access to research...

Read More about New Research: Dismantling barriers to research and clinical care for individuals with a vision impairment

X-linked retinitis pigmentosa RPGR gene therapy study update

The LUMEOS study was sponsored by Janssen Research & Development, LLC (a division of...

Read More about X-linked retinitis pigmentosa RPGR gene therapy study update

World Research Summary by Dr Catherine Civil

Hot Off The Press Check out below to see what new inherited retinal disease (IRD) therapies are in the pipeline!   Base...

Read More about World Research Summary by Dr Catherine Civil

Podcast: Mental Health and Rare Eye Diseases

Perspectives Podcast by Retina International Guest speaker: Matt Bolz-Johnson, a mental health lead at EURORDIS-Rare Diseases Europe Retina International's Perspectives Podcasts...

Read More about Podcast: Mental Health and Rare Eye Diseases

New Research: Navigating a hidden disability – Lived experiences and challenges of adults with early stage inherited retinal diseases

Inherited retinal diseases (IRDs) are genetic conditions that typically...

Read More about New Research: Navigating a hidden disability – Lived experiences and challenges of adults with early stage inherited retinal diseases

Perspectives of stem cell therapies for retinal conditions

Retina Australia has partnered with researchers at the University of New South Wales to...

Read More about Perspectives of stem cell therapies for retinal conditions

AAV-Based Gene Therapy for Retinal Diseases: A 2025 update

Retina Australia 2025 grant awardee, Dr Jiang-Hui (Sloan) Wang, PhD (Research Fellow), from the...

Read More about AAV-Based Gene Therapy for Retinal Diseases: A 2025 update

Vision improvements from Australia’s “second generation” bionic eye

Image is courtesy of Anna Carlile Summary  Advancements in retinal prosthesis...

Read More about Vision improvements from Australia’s “second generation” bionic eye

Podcast: The Australian Bionic Eye Project

Talking Eyes with Lien Trinh Guest speaker: Associate Professor Penelope Allen Talking Eyes is an Australian podcast dedicated to exploring the...

Read More about Podcast: The Australian Bionic Eye Project

5 Years of Luxturna

5 years of Luxturna - The first gene therapy for an IRD ERN-EYE hosted a webinar in late January 2025 to mark five years since the first gene therapy for...

Read More about 5 Years of Luxturna

Podcast: Fixing the Code for Inherited Retinal Diseases

Talking Eyes with Lien Trinh Guest speaker: Dr Tom Edwards In this Talking Retina episode, Fixing...

Read More about Podcast: Fixing the Code for Inherited Retinal Diseases

First treatment for geographic atrophy approved in Australia

Apellis' SYFOVRE® (pegcetacoplan) TGA Approved  Apellis Pharmaceuticals, Inc. announced today that Australia’s Therapeutic Goods Administration...

Read More about First treatment for geographic atrophy approved in Australia

Podcast: Dealing with inherited retinal disease

Talking Eyes with Lien Trinh Guest speaker: Professor Lauren Ayton Talking Eyes is an Australian podcast dedicated to exploring the latest...

Read More about Podcast: Dealing with inherited retinal disease

World Research Summary by Dr Catherine Civil

Hot Off The Press Welcome back to you all and I hope you all had a delightful festive season. I have...

Read More about World Research Summary by Dr Catherine Civil

Professor Jean Bennett – Melbourne November 2024

It was great for Rosemary and I to meet up with Professor Jean Bennett...

Read More about Professor Jean Bennett – Melbourne November 2024

New Research: Forty-year odyssey to Refsum disease diagnosis: impact of diagnostic delay on effective treatment

Often misdiagnosed as retinitis pigmentosa (RP), with the average...

Read More about New Research: Forty-year odyssey to Refsum disease diagnosis: impact of diagnostic delay on effective treatment

World Geographic Atrophy Day 2024

For World Geographic Atrophy Day 2024 on 5th December, Retina Australia is raising awareness for this leading cause of vision loss in people over...

Read More about World Geographic Atrophy Day 2024

Are there IRD treatments available?

One IRD treatment in Australia In Australia, there is currently one regulatory-approved therapy for an IRD, a gene therapy called Luxturna® (voretigene neparvovec-rzyl, Novartis), for...

Read More about Are there IRD treatments available?
  • Page:
  • 1
  • 2
  • 3
  • 4
  • 63 total stories
RA Australia logo Retina Australia is an ACNC registered charity - Visit ACNC
Follow us:
Visit our Youtube account Visit our Twitter account Visit our Facebook page Visit our Instagram account Visit our Linkedin page
  • 1800 999 870
  • info@retinaaustralia.com.au
  • Level 3 Ross House 247-251 Flinders Lane
    Melbourne VICTORIA 3000
  • About Us
  • Research
  • Inherited retinal disease
  • Contact Us
  • Support
  • Help Us
  • Donate
  • Subscribe

Retina Australia acknowledges the Traditional custodians of the land and pay our respects to Elders past, present and emerging.

© 2025 Retina Australia ABN 26 059 846 829

  • Privacy
  • Cookies
  • Security
  • Accessibility
  • Disclaimer
This website was verified to the level of AA conformance against WCAG 2.1 achieved on 17/9/2021
RA Australia logo
Retina Australia is an ACNC registered charity - Visit ACNC
  • 1800 999 870
  • info@retinaaustralia.com.au
  • Level 3 Ross House 247-251 Flinders Lane
    Melbourne VICTORIA 3000
  • About Us
  • Research
  • Inherited retinal disease
  • Contact Us
  • Support
  • Help Us
  • Donate
  • Subscribe
Follow us:
Visit our Youtube account Visit our Twitter account Visit our Facebook page Visit our Instagram account Visit our Linkedin page

© 2025 Retina Australia ABN 26 059 846 829

  • Privacy
  • Cookies
  • Security
  • Accessibility
  • Disclaimer

Help us show Australians affected by inherited retinal diseases they matter - Donate to the Retina Australia Annual Appeal today. CLICK HERE TO DONATE

Subscribe

Subscribe to our free monthly newsletter to keep up with the latest news related to inherited retinal diseases, including research updates and clinical trials.